AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CRMD · NASDAQ · Biotechnology

CorMedix (CRMD)

Sells an FDA-approved catheter lock solution and a portfolio of hospital anti-infective drugs across the US.

$8.54

Pre-market−0.08 (−0.87%)

At close$8.62(+2.80%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	1	11	31	39	40	104	129	127	102
Cost of revenue	0	0	1	1	1	1	2	2	11	21	22	25
Gross profit	0	0	−1	0	11	30	37	38	93	107	105	77
	10	16	16	16	14	17	17	18	42	48	41	34
Research & development	3	2	1	1	1	2	3	2	5	9	7	7
	8	13	15	15	13	15	14	16	37	40	34	28
Selling & marketing	4	0	6	7	7	8	4	6	11	16	13	12
General & administrative	4	0	9	8	7	7	10	10	25	24	22	15
Operating income	−10	−16	−17	−15	−3	13	20	20	51	59	64	43
	1	1	1	1	1	1	1	1	1	−3	−8	−4
Interest income	1	1	1	1	1	1	1	1	2	1	0	0
Interest expense	0	0	0	0	0	0	0	0	1	2	0	0
Other non-operating income	−1	−1	−1	−1	−1	−1	−1	−1	−2	1	8	−4
Income before tax	−10	−15	−16	−14	−3	13	21	20	53	56	56	39
Income tax expense	0	0	−1	0	0	0	0	1	−56	42	17	13
Net income from continuing operations	−10	−15	−14	−14	−3	13	21	20	109	14	39	26
Net income	−10	−15	−14	−14	−3	13	21	20	109	14	39	26
EPS, basic	−$0.17	−$0.26	−$0.25	−$0.25	−$0.05	$0.22	$0.32	$0.29	$1.42	$0.18	$0.48	$0.33
EPS, diluted	−$0.17	−$0.26	−$0.25	−$0.25	−$0.05	$0.22	$0.30	$0.28	$1.26	$0.15	$0.43	$0.29
Weighted average shares, basic	57	57	58	58	59	62	65	68	76	79	80	78
Weighted average shares, diluted	57	57	58	58	59	62	69	72	86	94	93	92
EBITDA	−10	−15	−16	−14	−3	14	21	21	57	69	66	57
Depreciation & amortization	0	0	0	0	0	0	0	0	4	10	11	10
EBIT	−10	−15	−16	−14	−3	13	21	20	54	58	56	47